nVision

nVision’s focus is on women’s health. The company created the first FDA-cleared device for collecting cells from the fallopian tubes, which aimed to enable earlier diagnosis of ovarian cancer. In 2018, nVision was acquired by Boston Scientific.

Healthcare & Biotech

Vision

nVision Medical was a female‑health focused company that pioneered the first FDA-cleared device capable of collecting cellular samples directly from the fallopian tubes—a breakthrough platform designed to enable earlier detection of ovarian cancer. Clinical studies showed the tissue collected by the device correlated strongly with post‑surgical diagnoses, positioning it as a potential tool for identifying malignancies before invasive surgery. In April 2018 Boston Scientific acquired nVision in a deal valued at up to $275 million (including $150 million upfront and $125 million in milestone payments), integrating its diagnostic innovation into a broader women’s oncology portfolio.

Sub-Industries

Medical Diagnostics Sensors

Cancer Diagnostics

Point-of-Care Diagnostics

Healthcare Technology

Medical Device Telehealth

Website

Location

Status

Top 40

Exited